Acetyl-L-Carnitine (ALCAR)

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published August 17, 2025•Updated February 20, 2026•Reviewed February 20, 2026

Indications

Primary Indications

Depression (especially in geriatric populations)Mild cognitive impairment and age-related cognitive declineNeuropathic pain (e.g., diabetic neuropathy, sciatica)Chronic fatigue syndrome

Mechanism

ALCAR facilitates transport of fatty acids into mitochondria for energy production and crosses the blood-brain barrier to support acetylcholine synthesis. It may improve mitochondrial efficiency, reduce oxidative stress, and exert neuroprotective and neurotrophic effects.

Dosing

Adult Dosing

max: 3,000 mg/day (studied doses)

start: 500 mg orally once or twice daily

titrate: Increase gradually as tolerated

usual range: 1,000–2,000 mg/day in divided doses

Dosage Forms

Capsules: 250 mg, 500 mg
Powder: variable formulations

Onset Duration

Mood and cognitive effects may emerge after 4–8 weeks; neuropathic pain improvements may be noted within weeks.

Adverse Effects

Common Side Effects

• nausea

• diarrhea

• restlessness

• fishy body odor

⚠️ Serious Side Effects

Seizures in susceptible individuals (rare)

Warnings

Critical Safety Information

→May increase risk of seizures in individuals with seizure disorders.
→Fishy odor may occur due to trimethylamine accumulation.
→Caution in renal impairment (metabolite accumulation possible).

Interactions

With: Valproic acid

Risk: Potential increased risk of hyperammonemia

Action: Monitor clinically

With: Warfarin

Risk: Possible potentiation of anticoagulant effect

Action: Monitor INR closely

With: Other stimulants or activating agents

Risk: Additive restlessness or insomnia

Action: Use caution

Monitoring

Mood and cognitive function
GI tolerance
Renal function in long-term use
Signs of agitation or restlessness

Special Populations

👶Pregnancy

Insufficient safety data; avoid unless prescribed.

🤱Breastfeeding

Not recommended; safety unknown.

👧Children & Adolescents (Under 18)

Limited data; avoid unless supervised by clinician.

👴Older Adults (65+)

May be beneficial in late-life depression and cognitive decline; monitor for restlessness.

Tapering

No formal taper required, but gradual reduction is prudent after long-term use to avoid sudden return of symptoms.

Clinical Notes

Most evidence supports use in older adults with depression or cognitive decline.
Appears well-tolerated compared to many antidepressants.
Potential mitochondrial and neurotrophic benefits make it of interest in neuropsychiatry.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists